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Abstract
Taurine is not only present in foods, tonics and nutrient drinks but is also used as a medicinal agent mainly for treatment of chronic heart
failure and liver disease. However, little is known about its influence on drug-metabolizing enzymes, especially cytochrome P450 (CYP), in
human. We examined whether taurine could affect the expression of CYP3A4 mRNA in the presence or absence of rifampicin (RFP), which
is a potent inducer of CYPs, with HepG2 cells. Taurine enhanced twice the induction of CYP3A4 mRNA by RFP, but did not affect the
expression by itself. This effect was both concentration- and time-dependent. On the other hand, taurine did not affect the induction by
phenobarbital. Taurine did not increase intracellular uptake of RFP. Therefore, we conclude that taurine is an enhancer for the induction of
CYP3A4 by RFP.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Taurine, 2-aminoethane sulfonic acid, is a major free h-
amino acid, but not a constituent of proteins. Taurine exists
free in the intracellular fluid, and is widely distributed in
many tissues including the myocardium, liver, skeletal
muscle, brain, retina, platelets and leukocytes. Taurine plays
a role in the maintenance of some physiological functions
[1–3]. The functions of taurine include osmoregulation [4],
cell membrane stabilization [5], antioxidation [6], detoxifi-
cation [3], neuromodulation [7,8], and brain and retinal
development [9]. Moreover, a number of studies have docu-
mented some pharmacological functions of taurine against
congestive heart failure [10], liver disease [11], hyperlipide-
mia [12] and epilepsy [13]. Although taurine is synthesized in
the liver from sulfur-containing amino acids, cysteine or
methionine, concern has been expressed about the adequacy
of endogenous sources, especially in neonates [14].
We have developed reverse transcription-competitive
PCR (RT-cPCR) methods to measure cytochrome P450
(CYP) mRNA quantitatively in human liver tissues [15].
RT-cPCR is one of the most sensitive tools for quantifying
the absolute levels of mRNA. Using this method with h-
actin as the internal standard, we measured the CYP
mRNA with a high degree of accuracy. We have also
demonstrated the usefulness of the human hepatoblastoma
HepG2 cell line combined with RT-cPCR as a tool for
evaluation of CYPs mRNA-induction by drugs. We also
reported a significant correlation between enzyme activity
and mRNA expression for CYP3A4 in human liver sam-
ples [16]. CYP3A4 recognizes and metabolizes a broad
range of structurally diverse therapeutic agents. As a
consequence, many clinically relevant drug–drug interac-
tions are associated with inhibition and/or induction of this
enzyme.
Strong concern with regard to the interaction between
drug and food has been growing for the past several years;
i.e. grapefruit juice [17] and St. John’s wort [18]. Recently
consumption of supplements, tonics and nutrient drinks
containing taurine has been rapidly increased. It is reported
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that CYP2E1 activity was reduced by taurine administration
in rats [19]. Moreover, a considerable number of studies
have described the effects of taurine on induction of several
mRNAs [20–22].
In this study, we observed the cooperative effect of
exogenous taurine on CYP3A4 mRNA induction triggered
by rifampicin (RFP).
2. Materials and methods
2.1. Chemicals
Taurine and h-alanine were obtained from Nacalai Tes-
que, Inc. (Kyoto, Japan). RFP was obtained from Sigma
Chemical Co. (St. Louis, MO), and phenobarbital was from
Wako Pure Chemical Industries (Osaka, Japan). Oligonu-
cleotide primers for CYP3A4 and h-actin were synthesized
by TaKaRa (Kyoto, Japan). All other chemicals used were
of the highest purity commercially available.
2.2. Cell culture and drug treatment
HepG2 cells were cultured in defined medium as
described previously [15]. Experimental observations were
made in cultures between 100 and 110 passages. Cells were
subcultured at confluence onto 12-well plates (seeding
density 1.0 106 cells/ml medium) and then grown to
50% confluence. The medium was changed to serum-free
medium or 20 mM taurine- or h-alanine-containing serum-
free medium, and cells were subsequently precultured for 24
h. RFP and phenobarbital were dissolved for treatment in
dimethylsulfoxide (DMSO) and diluted to various concen-
trations with serum-free medium. Cells were treated with
reagents for 3 to 72 h. The medium was renewed every 24 h.
After treatment, the cells were harvested and total RNAwas
obtained using a TRIzol RNA extraction kit (Life Technol-
ogies), according to the manufacturer’s protocol. The con-
centration of DMSO was 0.2% in both control and
experimental cultures.
2.3. Primer design and generation of DNA competitor
Forward and reverse primers were designed to amplify a
247-bp fragment from a specific region of the CYP3A4
gene and a 190-bp fragment of competitor [15].
Forward: 5VAGTGTGGGGCTTTTATGATG 3V
Reverse: 5VATACTGGGCAATGATAGGGA 3V
A pair of primers was also designed to amplify a 275-bp
fragment from a specific region of the h-actin gene and a
340-bp fragment of competitor [15].
Forward: 5VCAAGAGATGGCCACGGCTGCT 3V
Reverse: 5VTCCTTCTGCATCCTGTCGGCA 3V
The DNA competitors were generated using reagents
supplied with a commercial kit (Competitive DNA Con-
struction Kit, TaKaRa). Briefly, a 30-cycle PCR was carried
out on the cDNA using the relevant composite primers. A
second 35-cycle PCR was then carried out on 1 ml of the
first amplification product using the corresponding primers
for the target sequence.
2.4. RT-cPCR
cDNA synthesis was carried out as described previously
[15]. Competitive PCR was performed using a series of 10-
fold dilutions of DNA competitor (CYP3A4 ranging from
101 to 103 copies/Al; h-actin ranging from 104 to 106
copies/Al) with a constant amount of the first-strand cDNA.
The housekeeping gene h-actin was used for normalization
of expression of CYP mRNA to enable cross-comparison
among the different samples. Moreover, correction by h-
actin was used to control for equal amounts of mRNA used
in each reaction. cPCR was performed for 26 cycles for h-
actin, or 37 cycles for CYP3A4 of denaturation at 94 jC
for 30 s, annealing at 60 jC for 30 s and extension at 72 jC
for 30 s. Under these conditions, amplification of all cDNA
fragments produced a single product. To check for DNA
contamination, parallel reactions were performed for each
sample in which reverse transcriptase was omitted from the
RT reaction mixture. PCR product for each CYP was
verified by direct sequencing with one corresponding
primer (Dye-Terminator Cycle Sequencing Kit, Perkin-
Elmer).
2.5. Intracellular RFP concentration with or without
taurine pretreatment
The intracellular RFP content of HepG2 was measured
using an HPLC system consisting of an AS-400 Intelligent
Auto Sampler, L-5020 Column Oven, L-6020 Intelligent
Pump (Hitachi, Tokyo, Japan) and SI-1 NANOSPACE UV
detector (Shiseido, Tokyo, Japan). The HPLC column was
an ODSIII column (5 Am, 4.6 Am i.d. 250 mm: GL
Science) and the flow rate was 1.0 ml/min. Elution from
the column was monitored at 475 nm. The mobile phase
consisted of 60% 0.01 M sodium acetate and 40% acetoni-
trile. The cultured cells were rinsed twice with phosphate-
buffered saline, and then the cells were scraped off the dish,
added to 4 volumes of 37.5 Ag ml1 flufenamic acid and
methanol and centrifuged for 15 min at 15,000 g at 4 jC.
A 600-Al aliquot of the solution was injected into the
column after filtration.
2.6. Analysis of PCR products
Analysis of PCR products was performed according to
the previously described protocol [15]. The copy number of
each CYP isoform is expressed as copies/105 copies of h-
actin.
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3. Statistical analysis
Statistical evaluation of data was performed by one-way
analysis of variance followed by Bonferroni/Dunn multiple
range test. Significant differences from untreated control
cells are indicated as follows: *P < 0.05 and **P < 0.01.
4. Results
4.1. Effects of 20 mM taurine on CYP3A4 mRNA induction
by RFP
To determine the induction of CYP3A4 mRNA expres-
sion, HepG2 cells were treated with or without 50 AM RFP
in the absence or presence of 20 mM taurine. The amount
of CYP3A4 mRNA in RFP-treated cells was increased by
eightfold in comparison with untreated controls. Taurine
increased induction of CYP3A4 mRNA by RFP by
approximately twofold in comparison with cells treated
with RFP alone. No effect was observed in cells treated
with taurine by itself (Fig. 1). To determine the response of
HepG2 cells to varying concentrations of taurine, HepG2
cells were treated with 0, 0.2, 2, 10 or 20 mM taurine with
or without RFP for 72 h. Taurine increased induction of
CYP3A4 mRNA by RFP in a concentration-dependent
manner (Fig. 1).
4.2. Time course of CYP3A4 mRNA induction by RFP and/
or taurine
Time–response studies were performed to examine
CYP3A4 mRNA expression in HepG2 cells treated with
or without 50 AM RFP in the absence or presence of 20 mM
taurine. The amount of mRNA was measured in cells
harvested at 0, 3, 6, 24, 48 and 72 h. CYP3A4 mRNA
expression increased gradually in both RFP-treated cells and
RFP/taurine-treated cells until 72 h. No effect was observed
in control or taurine-treated cells. In comparison with RFP-
Fig. 1. Effects and concentration– response relationship of taurine treatment
on the expression of CYP3A4 mRNA in HepG2 cells. Total RNA was
extracted from HepG2 cells cultured for 72 h with or without 50 AM RFP.
These cells were treated with 0.2, 2, 10 or 20 mM taurine before adding
RFP. Values are the meansF S.E. of eight different experiments.
Significance was assessed statistically by one-way analysis of variance
followed by Bonferroni/Dunn’s PLSD multiple range test, *Significant
difference between groups ( P< 0.01).
Fig. 2. Time course of CYP3A4 mRNA expression with taurine treatment.
Total RNAwas extracted from HepG2 cells cultured for 3, 6, 24, 48 or 72 h
with or without 50 AM RFP. These cells were treated with 20 mM taurine
before adding RFP. Each point is the mean of two different experiments.
Fig. 3. Effects of taurine pretreatment with RFP in CYP3A4 mRNA
expression. Cells were exposed to taurine (20 mM) in the presence/absence
of phenobarbital (0.5 mM). HepG2 cells were pretreated for 24 h with
taurine before adding phenobarbital. Data are expressed as fold induction
over control. Values are the meansF S.E. of four different experiments.
Significance was assessed statistically by one-way analysis of variance
followed by Bonferroni/Dunn’s PLSD multiple range test for comparisons
between groups; *P< 0.05.
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treated cells, RFP/taurine-treated cells induced CYP3A4
mRNA in early time. As a result, RFP/taurine-treated cells
increased CYP3A4 mRNA level at 6 h, but RFP-treated
cells did not increase (Fig. 2).
4.3. Effects of taurine on CYP3A4 mRNA induction by
phenobarbital
To examine whether taurine affects induction of
CYP3A4 mRNA by phenobarbital, another typical inducer
of CYP3A4, HepG2 cells were treated with or without 0.5
mM phenobarbital in the absence or presence of 20 mM
taurine. The amount of CYP3A4 mRNA of phenobarbital-
treated cells was increased by sevenfold in comparison with
untreated controls. However, taurine did not affect CYP3A4
mRNA induced by phenobarbital (Fig. 3).
4.4. Effects of b-alanine on CYP3A4 mRNA induction by
RFP
HepG2 cells were treated with RFP and h-alanine, an
analog of taurine. RFP/h-alanine-treated cells showed no
significant enhancement of CYP3A4 mRNA compared with
RFP-treated cells. Apparently the amounts of CYP3A4
mRNA in taurine-treated cells and h-alanine-treated cells
were not increased in comparison with controls (Fig. 4).
4.5. Effects of taurine on intracellular RFP concentration
We measured intracellular RFP concentration in HepG2
treated with or without RFP and/or taurine. The concen-
trations of intracellular taurine are shown as milligram per
gram protein (Fig. 5). The results indicated that taurine did
not influence the intracellular RFP concentration.
5. Discussion
In this study, we investigated the impact of taurine on the
induction of CYP3A4 mRNA by RFP using HepG2 cells,
known to retain liver cell functions. Taurine enhanced
induction of CYP3A4 mRNA caused by RFP in a concen-
tration-dependent manner, while taurine alone did not affect
CYP3A4 mRNA expression. There have been some pre-
vious studies on the effects of taurine on mRNA induction
[20–22]. However, there has been no report demonstrating
effects of taurine on CYP mRNA expression. This is the
first report that taurine affects induction of CYP mRNA. In
contrast, h-alanine, an analog of taurine, did not affect
CYP3A4 mRNA expression. Capsaicin, xylitol and vitamin
E, commonly used as supplements or as components of
tonics and nutrient drinks, did not influence induction of
CYP3A4 mRNA (data not shown). Therefore, this effect of
taurine was not due to a nonspecific effect of amino acids or
substances of these supplements and drinks, but was a
unique action of taurine.
Fig. 4. Effects of h-alanine as a taurine analog on the expression of
CYP3A4 mRNA. Data are expressed as fold induction over control. Each
bar represents the meanF S.E. obtained from three different cultures.
Statistical evaluation of data was performed by ANOVA followed by
Bonferroni/Dunn multiple range test for comparisons between groups;
*P < 0.01.
Fig. 5. Intra cellular concentration of Rifampicin with or without Taurine
pretreatment. (A) A typical chromatogram. (B) Concentration of rifampicin
with or without taurine in HepG2 cells. Values are meansF S.E. of 10
different experiments.
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CYP3A4 mRNA expression increased gradually in both
RFP-treated and RFP/taurine-treated cells until 72 h. In
comparison with RFP-treatment, RFP/taurine-treatment
quickly induced CYP3A4 mRNA, and the increase in both
groups occurs in parallel from 24 to 72 h. RFP increased
CYP3A4 mRNA expression in a concentration-dependent
manner [23,24]. These results suggested that taurine might
increase the concentration of RFP in the HepG2. However,
no differences in the concentration of RFP between RFP-
treated and RFP/taurine-treated HepG2 cells were obtained.
This result strongly supports that taurine influences
CYP3A4 mRNA induction, but not through the elevation
of intercellular RFP concentration in HepG2 cell. In addi-
tion, considering the stability of mRNA, taurine might not
affect it since taurine did not affect the phenobarbital-
mediated induction. Therefore, we suppose that taurine
might activate a specific transcription factors.
In most previous studies, the degree of CYP mRNA
induction, including CYP3A, was decreased and only the
fetal form (CYP3A7) was detected in HepG2 cells using
Northern blot [25]. We also understood that it is difficult to
detect the induction of CYP3A4 in HepG2 cells using
Northern blot. Therefore, we have established the method
for evaluating the degree of CYP3A4 mRNA induction,
using a combination of the HepG2 cells and RT-PCR by the
specific primers[15,16]. Since then, we have evaluated the
degree of CYP3A4 induction by many drugs (e.g. RFP, PB,
dexamethasone etc), which was reported in human hepato-
cytes by this method (data not shown). Therefore, we
believe that this method is very useful tool for the evaluation
of the CYP3A4 induction.
Recent observations have provided evidence that the
pregnane X receptor (PXR), an orphan member of the
steroid/retinoid/thyroid hormone receptor superfamily of
ligand-activated transcription factors [26–28], is a key
regulator of CYP3A transcription in a wide variety of
species. PXR is a promiscuous receptor that mediates
signals from xenobiotics as well as natural hormones,
including RFP, pregnenolone 16 a-carbonitrile and dexa-
methasone, on CYP3A gene induction [26–28]. On the
other hand, constitutive activated receptor (CAR) has been
implicated in the phenobarbital-mediated induction of
CYP3A [29,30]. Our results clearly demonstrate that taurine
promotes the induction of CYP3A4 mRNA caused by RFP,
but not the induction by phenobarbital. Thus, it is plausible
that taurine influences PXR-modulated transcription activ-
ity, but not through CAR.
The present observations could not point out whether the
activation of induction of CYP3A4 by taurine is mediated
via PXR directly or indirectly. RFP inhibits the hepatocel-
lular bile salt export pump and subsequently increases the
concentration of bile acids in hepatocytes. As a result, RFP
causes cholestasis in rat liver [31]. On the other hand, it is
possible that bile acids conjugate with taurine and its
composition might be influenced by taurine [32,33]. Bile
acid is a kind of steroid derivative, and the steroid hormone
is a potent inducer of CYP3A4 mRNA via PXR activation.
Therefore, it is reasonable to consider that bile acids could
activate PXR and subsequently induce CYP3A4. It was
recently reported that PXR serves as a functional bile acids
receptor, and lithocholic acid, which is a kind of bile acid,
induces CYP3A mRNA [34,35]. We propose the mecha-
nism that taurine-induced activation of CYP3A4 induction
is probably mediated by bile acids.
In conclusion, we have shown that taurine enhances
CYP3A4 induction by RFP. Attention should be paid to
drug interactions when taurine-containing medicinal agents,
foods and drinks are administered together with both RFP
and drugs metabolized mainly by CYP3A4. We have to
verify if it would happen in vivo. However, it is another
point to emphasize that taurine possibly improves hepatic
cholestasis caused by RFP and facilitates detoxification of
xenobiotics.
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